| 6.43 0.29 (4.72%) | 09-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.6 | 1-year : | 9.51 |
| Resists | First : | 7.36 | Second : | 8.14 |
| Pivot price | 7.07  |
|||
| Supports | First : | 6.09 | Second : | 5.06 |
| MAs | MA(5) : | 6.52 |
MA(20) : | 7.22 |
| MA(100) : | 6.63 |
MA(250) : | 7.07 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 8.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 9.55 | Low : | 4.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DERM ] has closed above bottom band by 17.0%. Bollinger Bands are 59.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.49 - 6.53 | 6.53 - 6.57 |
| Low: | 6.02 - 6.07 | 6.07 - 6.11 |
| Close: | 6.36 - 6.43 | 6.43 - 6.49 |
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Sat, 19 Sep 2026
Journey Medical: A Small Pharma With A Large Growth Opportunity (NASDAQ:DERM) - Seeking Alpha
Fri, 11 Sep 2026
Journey Medical Corporation $DERM Shares Sold by Opaleye Management Inc. - marketbeat.com
Tue, 08 Sep 2026
Nine FDA-approved skin drugs are marketed by Journey Medical. Its CEO will join two investor events. - Stock Titan
Tue, 08 Sep 2026
Journey Medical Corporation to Participate in September 2026 Investor Conferences - GlobeNewswire
Mon, 07 Sep 2026
DERM 8-K Filings - Journey Medical Corporation SEC 8-K - Stock Titan
Wed, 12 Aug 2026
Journey Medical Q2 Earnings Call Highlights - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 22 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 31.7 (%) |
| Held by Institutions | 48.5 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 3,050 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | -9 % |
| Operating Margin | 2.4 % |
| Return on Assets (ttm) | -2.1 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | 23.2 % |
| Gross Profit (p.s.) | 2 |
| Sales Per Share | 3.06 |
| EBITDA (p.s.) | 0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -29.23 |
| PEG Ratio | 0 |
| Price to Book value | 5.54 |
| Price to Sales | 2.09 |
| Price to Cash Flow | -19.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|